

Ingela Fritzson resigns from the Board of Directors of Magle Group

Ingela Fritzson has today informed Magle Chemoswed Holding AB that she resigns from her position as employee representative in Magle Group's Board of Directors, as of today 26 February 2025. Unionen, which appointed Ingela Fritzson, has not yet appointed a replacement.

For enquiries, please contact:

Magle Group

Justin Pierce, CEO

Email: justin.pierce@maglechemoswed.com

Telephone: +46 (0)70 593 58 21

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmaceut.com and www.maglebiopolymers.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Attachments

[Ingela Fritzson resigns from the Board of Directors of Magle Group](#)